Daiki Iwami1, C Colin Brinkman, Jonathan S Bromberg. 1. 1 Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD. 2 Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD. 3 Department of Surgery, University of Maryland School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: Circulation of leukocytes via blood, tissue and lymph is integral to adaptive immunity. Afferent lymphatics form CCL21 gradients to guide dendritic cells and T cells to lymphatics and then to draining lymph nodes (dLN). Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 (VEGFR-3) are the major lymphatic growth factor and receptor. We hypothesized these molecules also regulate chemokine gradients and lymphatic migration. METHODS: CD4 T cells were injected into the foot pad or ear pinnae, and migration to afferent lymphatics and dLN quantified by flow cytometry or whole mount immunohistochemistry. Vascular endothelial growth factor receptor 3 or its signaling or downstream actions were modified with blocking monoclonal antibodies (mAbs) or other reagents. RESULTS: Anti-VEGFR-3 prevented migration of CD4 T cells into lymphatic lumen and significantly decreased the number that migrated to dLN. Anti-VEGFR-3 abolished CCL21 gradients around lymphatics, although CCL21 production was not inhibited. Heparan sulfate (HS), critical to establish CCL21 gradients, was down-regulated around lymphatics by anti-VEGFR-3 and this was dependent on heparanase-mediated degradation. Moreover, a Phosphoinositide 3-kinase (PI3K)α inhibitor disrupted HS and CCL21 gradients, whereas a PI3K activator prevented the effects of anti-VEGFR-3. During contact hypersensitivity, VEGFR-3, CCL21, and HS expression were all attenuated, and anti-heparanase or PI3K activator reversed these effects. CONCLUSIONS: Vascular endothelial growth factor C/VEGFR-3 signaling through PI3Kα regulates the activity of heparanase, which modifies HS and CCL21 gradients around lymphatics. The functional and physical linkages of these molecules regulate lymphatic migration from tissues to dLN. These represent new therapeutic targets to influence immunity and inflammation.
BACKGROUND: Circulation of leukocytes via blood, tissue and lymph is integral to adaptive immunity. Afferent lymphatics form CCL21 gradients to guide dendritic cells and T cells to lymphatics and then to draining lymph nodes (dLN). Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 (VEGFR-3) are the major lymphatic growth factor and receptor. We hypothesized these molecules also regulate chemokine gradients and lymphatic migration. METHODS:CD4 T cells were injected into the foot pad or ear pinnae, and migration to afferent lymphatics and dLN quantified by flow cytometry or whole mount immunohistochemistry. Vascular endothelial growth factor receptor 3 or its signaling or downstream actions were modified with blocking monoclonal antibodies (mAbs) or other reagents. RESULTS: Anti-VEGFR-3 prevented migration of CD4 T cells into lymphatic lumen and significantly decreased the number that migrated to dLN. Anti-VEGFR-3 abolished CCL21 gradients around lymphatics, although CCL21 production was not inhibited. Heparan sulfate (HS), critical to establish CCL21 gradients, was down-regulated around lymphatics by anti-VEGFR-3 and this was dependent on heparanase-mediated degradation. Moreover, a Phosphoinositide 3-kinase (PI3K)α inhibitor disrupted HS and CCL21 gradients, whereas a PI3K activator prevented the effects of anti-VEGFR-3. During contact hypersensitivity,VEGFR-3, CCL21, and HS expression were all attenuated, and anti-heparanase or PI3K activator reversed these effects. CONCLUSIONS:Vascular endothelial growth factor C/VEGFR-3 signaling through PI3Kα regulates the activity of heparanase, which modifies HS and CCL21 gradients around lymphatics. The functional and physical linkages of these molecules regulate lymphatic migration from tissues to dLN. These represent new therapeutic targets to influence immunity and inflammation.
Authors: Kathrin Schumann; Tim Lämmermann; Markus Bruckner; Daniel F Legler; Julien Polleux; Joachim P Spatz; Gerold Schuler; Reinhold Förster; Manfred B Lutz; Lydia Sorokin; Michael Sixt Journal: Immunity Date: 2010-05-13 Impact factor: 31.745
Authors: Antti I Nykänen; Henrik Sandelin; Rainer Krebs; Mikko A I Keränen; Raimo Tuuminen; Terhi Kärpänen; Yan Wu; Bronislaw Pytowski; Petri K Koskinen; Seppo Ylä-Herttuala; Kari Alitalo; Karl B Lemström Journal: Circulation Date: 2010-03-15 Impact factor: 29.690
Authors: Edward McKenzie; Kathryn Young; Margaret Hircock; James Bennett; Maina Bhaman; Robert Felix; Paul Turner; Alasdair Stamps; David McMillan; Giles Saville; Stanley Ng; Sean Mason; Daniel Snell; Darren Schofield; Haiping Gong; Reid Townsend; John Gallagher; Martin Page; Raj Parekh; Colin Stubberfield Journal: Biochem J Date: 2003-07-15 Impact factor: 3.857
Authors: Dontscho Kerjaschki; Heinrich M Regele; Isabella Moosberger; Katalyn Nagy-Bojarski; Bruno Watschinger; Afschin Soleiman; Peter Birner; Sigurd Krieger; Anny Hovorka; Georg Silberhumer; Pirjo Laakkonen; Tatiana Petrova; Brigitte Langer; Ingrid Raab Journal: J Am Soc Nephrol Date: 2004-03 Impact factor: 10.121
Authors: Ruolin Guo; Quan Zhou; Steven T Proulx; Ronald Wood; Rui-Cheng Ji; Christopher T Ritchlin; Bronislaw Pytowski; Zhenping Zhu; Yong-Jun Wang; Edward M Schwarz; Lianping Xing Journal: Arthritis Rheum Date: 2009-09
Authors: Reto Huggenberger; Stefan Ullmann; Steven T Proulx; Bronislaw Pytowski; Kari Alitalo; Michael Detmar Journal: J Exp Med Date: 2010-09-13 Impact factor: 14.307
Authors: Echoe M Bouta; Richard D Bell; Homaira Rahimi; Lianping Xing; Ronald W Wood; Clifton O Bingham; Christopher T Ritchlin; Edward M Schwarz Journal: Nat Rev Rheumatol Date: 2018-01-11 Impact factor: 20.543
Authors: Peter Baluk; Ram P Naikawadi; Shineui Kim; Felipe Rodriguez; Dongwon Choi; Young-Kwon Hong; Paul J Wolters; Donald M McDonald Journal: Am J Pathol Date: 2020-10-08 Impact factor: 4.307
Authors: John P Sundberg; C Herbert Pratt; Kathleen A Silva; Victoria E Kennedy; Timothy M Stearns; Beth A Sundberg; Lloyd E King; Harm HogenEsch Journal: Exp Mol Pathol Date: 2016-03-06 Impact factor: 3.362
Authors: Ayodeji Adegunsoye; Cara L Hrusch; Catherine A Bonham; Mohammad R Jaffery; Kelly M Blaine; Meghan Sullivan; Matthew M Churpek; Mary E Strek; Imre Noth; Anne I Sperling Journal: Front Immunol Date: 2016-11-23 Impact factor: 7.561
Authors: Yanbao Xiong; C Colin Brinkman; Konrad S Famulski; Emmanuel F Mongodin; Colin J Lord; Keli L Hippen; Bruce R Blazar; Jonathan S Bromberg Journal: Sci Rep Date: 2017-05-09 Impact factor: 4.379
Authors: G D García Nores; D A Cuzzone; N J Albano; G E Hespe; R P Kataru; J S Torrisi; J C Gardenier; I L Savetsky; S Z Aschen; M D Nitti; B J Mehrara Journal: Int J Obes (Lond) Date: 2016-05-20 Impact factor: 5.095